Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Liver Diseases

Free Subscription 16.10.2023 2 AJR Am J Roentgenol 3 Am J Gastroenterol 1 Am J Pathol 4 Anticancer Res 3 Biochem Biophys Res Commun 3 BMC Cancer 1 BMC Gastroenterol 4 Clin Res Hepatol Gastroenterol 2 Dig Dis Sci 4 Eur Radiol 2 Gastrointest Endosc 3 Gut 6 Hepatology 2 Indian J Gastroenterol 1 J Gastroenterol 3 J Gastroenterol Hepatol 7 J Hepatol 2 Radiology 3 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. ZHANG LX, Tang A
   Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Counterpoint-Hepatobiliary Contrast Agents Improve Detection and Characterization.
   AJR Am J Roentgenol. 2023 Oct 4. doi: 10.2214/AJR.23.30140.
   PubMed        
   
   
2. TAMANDL D, Schima W
   Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Point-Why Extracellular Contrast Agents Are Superior for This Task.
   AJR Am J Roentgenol. 2023 Oct 4. doi: 10.2214/AJR.23.30254.
   PubMed        
   
   

   
   Am J Gastroenterol

3. OZTURK NB, Jamil LH, Tapper EB
   Diagnostic Performance of the ICD-10 Code K76.82 for Hepatic Encephalopathy in Patients with Cirrhosis.
   Am J Gastroenterol. 2023 Oct 13. doi: 10.14309/ajg.0000000000002560.
   PubMed         Abstract available
   
   
4. PRASOPPOKAKORN T, Panarat P
   Disseminated Melioidosis infection involving hepatosplenomegaly and massive extramedullary hematopoiesis.
   Am J Gastroenterol. 2023 Oct 4. doi: 10.14309/ajg.0000000000002549.
   PubMed        
   
   
5. PULASKI M, Bittermann T, Taddei TH, Kaplan DE, et al
   The Association between Homelessness and Key Liver-Related Outcomes in Veterans with Cirrhosis.
   Am J Gastroenterol. 2023 Oct 2. doi: 10.14309/ajg.0000000000002535.
   PubMed         Abstract available
   
   

   
   Am J Pathol

6. FENG R, Tong C, Lin T, Liu H, et al
   Insulin determines TGF-beta effects on HNF4alpha transcription in hepatocytes.
   Am J Pathol. 2023 Oct 9:S0002-9440(23)00365-6. doi: 10.1016/j.ajpath.2023.
   PubMed         Abstract available
   
   

   
   Anticancer Res

7. YANG JD, Yueh PF, Liao TL, Chen YT, et al
   Unlocking Synergistic Potential: Enhancing Regorafenib Efficacy in Hepatocellular Carcinoma Through Combination Therapy With 18beta-Glycyrrhetinic Acid.
   Anticancer Res. 2023;43:4403-4412.
   PubMed         Abstract available
   
   
8. WANG CC, Fan WL, Liu TT, Pang ST, et al
   Impact of Genomic Alterations on the Clinical Outcome of Patients With Hepatitis B-related Hepatocellular Carcinoma Receiving Curative Surgery: A Retrospective Cohort Study.
   Anticancer Res. 2023;43:4709-4722.
   PubMed         Abstract available
   
   
9. LEE YJ, Kim KC, Lee JM, Lim JM, et al
   Development of Polyethylene Glycol-based Hydrogels Optimized for In Vitro 3D Culture of HepG2 Hepatocarcinoma Cells.
   Anticancer Res. 2023;43:4373-4377.
   PubMed         Abstract available
   
   
10. YAMAMURA K, Beppu T, Miyata T, Mima K, et al
    Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy.
    Anticancer Res. 2023;43:4285-4293.
    PubMed         Abstract available
    
    

    
    Biochem Biophys Res Commun

11. KIM J, Choi A, Kwon YH
    Maternal low-protein diet alters hepatic lipid accumulation and gene expression related to glucose metabolism in young adult mouse offspring fed a postweaning high-fat diet.
    Biochem Biophys Res Commun. 2023;682:193-198.
    PubMed         Abstract available
    
    
12. WANG S, Yi W, Xu Z, Shi M, et al
    PYCR2 promotes growth and aerobic glycolysis in human liver cancer by regulating the AKT signaling pathway.
    Biochem Biophys Res Commun. 2023;680:15-24.
    PubMed         Abstract available
    
    
13. JOUENNE A, Hamici K, Varlet I, Sourdon J, et al
    Relationship of cardiac remodeling and perfusion alteration with hepatic lipid metabolism in a prediabetic high fat high sucrose diet female rat model.
    Biochem Biophys Res Commun. 2023;682:207-215.
    PubMed         Abstract available
    
    

    
    BMC Cancer

14. LIU Y, Fu S, Yu X, Zhang J, et al
    Model containing sarcopenia and visceral adiposity can better predict the prognosis of hepatocellular carcinoma: a multicenter study.
    BMC Cancer. 2023;23:969.
    PubMed         Abstract available
    
    
15. ZHAO C, Tong L, Liu B, Qi F, et al
    Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer.
    BMC Cancer. 2023;23:973.
    PubMed         Abstract available
    
    
16. GUO J, Zhao J, Xu Q, Huang D, et al
    MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib.
    BMC Cancer. 2023;23:967.
    PubMed         Abstract available
    
    

    
    BMC Gastroenterol

17. SADEGHIANPOUR Z, Cheraghian B, Farshchi HR, Asadi-Lari M, et al
    Non-alcoholic fatty liver disease and socioeconomic determinants in an Iranian cohort study.
    BMC Gastroenterol. 2023;23:350.
    PubMed         Abstract available
    
    

    
    Clin Res Hepatol Gastroenterol

18. DI GIORGIO A, Sciveres M, Fuoti M, Sonzogni A, et al
    Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency.
    Clin Res Hepatol Gastroenterol. 2023;47:102185.
    PubMed         Abstract available
    
    
19. DUMONT C, Lanthier N, Dahlqvist G
    Fibrosis and steatosis of the liver graft: Are non-invasive tests useful? A short review.
    Clin Res Hepatol Gastroenterol. 2023;47:102194.
    PubMed         Abstract available
    
    
20. CHAIBI S, Larrey E, Couty JP, Sultanik P, et al
    Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
    Clin Res Hepatol Gastroenterol. 2023;47:102199.
    PubMed         Abstract available
    
    
21. DENG K, Yang F, Liu X, Deng M, et al
    Adult Kasabach-Merritt syndrome secondary to hepatic angiosarcoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102211.
    PubMed        
    
    

    
    Dig Dis Sci

22. KILANI Y, Kamal SAF, Vikash F, Vikash S, et al
    Correction to: Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma in the United States: An Update.
    Dig Dis Sci. 2023 Oct 13. doi: 10.1007/s10620-023-08131.
    PubMed        
    
    
23. WANG L, Zhang Y, Li J, Guo S, et al
    A Nomogram of Magnetic Resonance Imaging for Preoperative Assessment of Microvascular Invasion and Prognosis of Hepatocellular Carcinoma.
    Dig Dis Sci. 2023 Oct 4. doi: 10.1007/s10620-023-08022.
    PubMed         Abstract available
    
    

    
    Eur Radiol

24. DELAGNES A, Roux M, Vilgrain V, Guiu B, et al
    Fat-containing hepatocellular carcinoma in patients with cirrhosis: proposal of a diagnostic modification regarding enhancement characteristics.
    Eur Radiol. 2023 Oct 11. doi: 10.1007/s00330-023-10236.
    PubMed         Abstract available
    
    
25. YU Q, Ungchusri E, Pillai A, Liao CY, et al
    Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma.
    Eur Radiol. 2023 Oct 9. doi: 10.1007/s00330-023-10203.
    PubMed         Abstract available
    
    
26. HUANG P, Wu F, Hou K, Zhou C, et al
    Diagnostic algorithm for subcentimeter hepatocellular carcinoma using alpha-fetoprotein and imaging features on gadoxetic acid-enhanced MRI.
    Eur Radiol. 2023 Oct 4. doi: 10.1007/s00330-023-10214.
    PubMed         Abstract available
    
    
27. ZAFAR S, Elbanna KY, Todd AWM, Guimaraes L, et al
    Can absolute arterial phase hyperenhancement improve sensitivity of detection of hepatocellular carcinoma in indeterminate nodules on CT?
    Eur Radiol. 2023 Sep 30. doi: 10.1007/s00330-023-10237.
    PubMed         Abstract available
    
    

    
    Gastrointest Endosc

28. DAUGHERTY TT, Genere JR
    Endoscopic findings of a transjugular intrahepatic portosystemic shunt stent eroding into the biliary tract.
    Gastrointest Endosc. 2023 Oct 6:S0016-5107(23)02951.
    PubMed        
    
    
29. GOPAKUMAR H, Dhillon S, Puli SR
    Lumen apposing metal stent for the management of symptomatic hepatic cyst.
    Gastrointest Endosc. 2023 Sep 28:S0016-5107(23)02910.
    PubMed        
    
    

    
    Gut

30. EN LI CHO E, Ang CZ, Quek J, Fu CE, et al
    Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
    Gut. 2023;72:2138-2148.
    PubMed         Abstract available
    
    
31. CHOI WM, Kim GA, Choi J, Choi GH, et al
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
    PubMed         Abstract available
    
    
32. 
    Correction: Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
    Gut. 2023;72:e4.
    PubMed        
    
    

    
    Hepatology

33. VONADA A, Wakefield L, Martinez M, Harding CO, et al
    Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation.
    Hepatology. 2023 Oct 12. doi: 10.1097/HEP.0000000000000631.
    PubMed         Abstract available
    
    
34. CHEN P, Dong Z, Zhu W, Chen J, et al
    Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for hepatocellular carcinoma.
    Hepatology. 2023 Oct 11. doi: 10.1097/HEP.0000000000000623.
    PubMed         Abstract available
    
    
35. MA S, Chew V
    Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
    Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
    PubMed        
    
    
36. THIELE M, Johansen S, Israelsen M, Trebicka J, et al
    Non-invasive assessment of hepatic decompensation.
    Hepatology. 2023 Oct 6. doi: 10.1097/HEP.0000000000000618.
    PubMed         Abstract available
    
    
37. PENNISI G, Enea M, Romero-Gomez M, Bugianesi E, et al
    Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria.
    Hepatology. 2023 Oct 2. doi: 10.1097/HEP.0000000000000616.
    PubMed         Abstract available
    
    
38. NAHON P, Layese R, Ganne-Carrie N, Moins C, et al
    The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis.
    Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615.
    PubMed         Abstract available
    
    

    
    Indian J Gastroenterol

39. JOTHIMANI D, Paramasivam R, Manoharan M, Ramachandran H, et al
    Fecal calprotectin in patients with liver cirrhosis.
    Indian J Gastroenterol. 2023 Oct 12. doi: 10.1007/s12664-023-01450.
    PubMed         Abstract available
    
    
40. AARON R, Premkumar K, Chapla A, Vijayalekshmi B, et al
    Focused panel sequencing points to genetic predisposition in non-cirrhotic intrahepatic portal hypertension patients in India.
    Indian J Gastroenterol. 2023 Oct 5. doi: 10.1007/s12664-023-01454.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

41. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

42. SHOU D, Luo Q, Tang W, Cao C, et al
    Hepatobiliary and pancreatic: Multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota.
    J Gastroenterol Hepatol. 2023 Oct 3. doi: 10.1111/jgh.16359.
    PubMed         Abstract available
    
    
43. GIRI S, Singh A, Kolhe K, Kale A, et al
    Reply: Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Oct 7. doi: 10.1111/jgh.16378.
    PubMed        
    
    
44. OH JH, Saeed WK, Kim HY, Lee SM, et al
    Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis.
    J Gastroenterol Hepatol. 2023 Oct 9. doi: 10.1111/jgh.16368.
    PubMed         Abstract available
    
    

    
    J Hepatol

45. SHA M, Cao J, Xia Q
    Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: what are the optimal criteria?
    J Hepatol. 2023 Oct 9:S0168-8278(23)05162-0. doi: 10.1016/j.jhep.2023.
    PubMed        
    
    
46. CHE-TO LAI J, Lai-Hung Wong G, Cheuk-Fung Yip T
    Reply to "For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?".
    J Hepatol. 2023 Oct 9:S0168-8278(23)05165-6. doi: 10.1016/j.jhep.2023.
    PubMed        
    
    
47. GRONBAEK L, Gronbaek H
    Editorial: Hepatocellular carcinoma in autoimmune hepatitis remains rare.
    J Hepatol. 2023 Oct 9:S0168-8278(23)05159-0. doi: 10.1016/j.jhep.2023.
    PubMed        
    
    
48. ABERG F, Savikko J, Eerola V, Nordin A, et al
    High prevalence of liver fibrosis and cirrhosis in a nationwide sample of organ donors with liver histology.
    J Hepatol. 2023 Oct 7:S0168-8278(23)05145-0. doi: 10.1016/j.jhep.2023.
    PubMed        
    
    
49. COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
    Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
    J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
    PubMed         Abstract available
    
    
50. LU W
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!
    J Hepatol. 2023 Oct 3:S0168-8278(23)05142-5. doi: 10.1016/j.jhep.2023.
    PubMed        
    
    
51. KANG MG, Lee CH, Shen C, Kim JS, et al
    Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea.
    J Hepatol. 2023 Oct 10:S0168-8278(23)05166-8. doi: 10.1016/j.jhep.2023.
    PubMed        
    
    

    
    Radiology

52. VIANNA P, Calce SI, Boustros P, Larocque-Rigney C, et al
    Comparison of Radiologists and Deep Learning for US Grading of Hepatic Steatosis.
    Radiology. 2023;309:e230659.
    PubMed         Abstract available
    
    
53. KURODA H, Oguri T, Kamiyama N, Toyoda H, et al
    Multivariable Quantitative US Parameters for Assessing Hepatic Steatosis.
    Radiology. 2023;309:e230341.
    PubMed         Abstract available
    
    

    
    Transplant Proc

54. SAMBOMMATSU Y, Bruno DA, Imai D, Lee SD, et al
    Domino Liver Transplantation for Unresectable Colon Cancer Liver Metastasis From a Donor With Heterozygous Familial Hyperlipidemia: A Case Report.
    Transplant Proc. 2023 Sep 1:S0041-1345(23)00481.
    PubMed         Abstract available
    
    
55. ALIM A, Karatas C, Akbulut A, Oguz BH, et al
    Living Donor-Initiated Domino Split-Liver Transplantation in Pediatric Setup: A Case Report With Literature Review.
    Transplant Proc. 2023 Aug 28:S0041-1345(23)00480.
    PubMed         Abstract available
    
    
56. CHAIRI MHM, Arias ABV, Zurbano MS, Rios PD, et al
    Reassessment After Locoregional Treatment of Hepatocellular Carcinoma Previous Liver Transplantation: Is MRI Necessary for All Patients?
    Transplant Proc. 2023 Oct 7:S0041-1345(23)00588.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.